These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 28848246)

  • 1. Advances in Immunotherapy for Melanoma: A Comprehensive Review.
    Rodríguez-Cerdeira C; Carnero Gregorio M; López-Barcenas A; Sánchez-Blanco E; Sánchez-Blanco B; Fabbrocini G; Bardhi B; Sinani A; Guzman RA
    Mediators Inflamm; 2017; 2017():3264217. PubMed ID: 28848246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.
    Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J
    Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
    Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to overcome obstacles to successful immunotherapy of melanoma.
    Pandolfi F; Cianci R; Lolli S; Dunn IS; Newton EE; Haggerty TJ; Boyle LA; Kurnick JT
    Int J Immunopathol Pharmacol; 2008; 21(3):493-500. PubMed ID: 18831916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on immunotherapy for melanoma.
    Ribas A
    J Natl Compr Canc Netw; 2006 Aug; 4(7):687-94. PubMed ID: 16884670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A role of immunotherapy in metastatic malignant melanoma.
    Allen T; Gundrajakuppam L
    Cent Nerv Syst Agents Med Chem; 2012 Sep; 12(3):182-8. PubMed ID: 22697295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.
    Aarntzen EH; Bol K; Schreibelt G; Jacobs JF; Lesterhuis WJ; Van Rossum MM; Adema GJ; Figdor CG; Punt CJ; De Vries IJ
    Cancer Res; 2012 Dec; 72(23):6102-10. PubMed ID: 23010076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
    Shadbad MA; Hajiasgharzadeh K; Derakhshani A; Silvestris N; Baghbanzadeh A; Racanelli V; Baradaran B
    Front Immunol; 2021; 12():623639. PubMed ID: 33692796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine Strategy in Melanoma.
    Kwak M; Leick KM; Melssen MM; Slingluff CL
    Surg Oncol Clin N Am; 2019 Jul; 28(3):337-351. PubMed ID: 31079792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for advanced melanoma: Current knowledge and future directions.
    Nakamura K; Okuyama R
    J Dermatol Sci; 2016 Aug; 83(2):87-94. PubMed ID: 27302423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients.
    Tüting T
    Pigment Cell Melanoma Res; 2013 Jul; 26(4):441-56. PubMed ID: 23617831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
    Yang S; Linette GP; Longerich S; Haluska FG
    J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New therapeutic approachs in melanoma].
    Mortier L; Marchetti P; Gordower L; Charbonnier-Hatzfeld AS; Toungouz M; Velu T
    Rev Med Brux; 2004 Jun; 25(3):153-9. PubMed ID: 15291447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral immunotherapy for melanoma.
    Singh M; Overwijk WW
    Cancer Immunol Immunother; 2015 Jul; 64(7):911-21. PubMed ID: 26050024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
    Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
    Front Immunol; 2018; 9():14. PubMed ID: 29403496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for melanoma.
    Komenaka I; Hoerig H; Kaufman HL
    Clin Dermatol; 2004; 22(3):251-65. PubMed ID: 15262312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer.
    Rojas-Sepúlveda D; Tittarelli A; Gleisner MA; Ávalos I; Pereda C; Gallegos I; González FE; López MN; Butte JM; Roa JC; Fluxá P; Salazar-Onfray F
    Cancer Immunol Immunother; 2018 Dec; 67(12):1897-1910. PubMed ID: 29600445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Commotion in the Skin: Developing Melanoma Immunotherapies.
    Brenner E; Röcken M
    J Invest Dermatol; 2022 Aug; 142(8):2055-2060. PubMed ID: 35339277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?
    Tietze JK; Sckisel GD; Hsiao HH; Murphy WJ
    Int Rev Immunol; 2011; 30(5-6):238-93. PubMed ID: 22053969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.